Home › Chronic Lymphocytic Leukemia › Massachusetts
Pag-aaral pangklinika para sa Chronic Lymphocytic Leukemia sa Massachusetts
33 pag-aaral para sa Chronic Lymphocytic Leukemia ang naghahanap ng mga kalahok sa mga site sa Massachusetts.
Mga Lungsod sa Massachusetts
Opisyal na teksto ng pag-aaral (English)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Tufts Medical Center Cancer Center Stoneham, Stoneham
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT04269902A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Boston Medical Center, Boston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06588478Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 3
Edad 65 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07321652A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 28, 2026 · NCT06564038A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT06697184CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- DFCI/BWH Brigham and Women's Hospital, Boston
Nagre-recruitPhase 2Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 23, 2026 · NCT06059391MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
- Research Site, Boston
Nagre-recruitPhase 2
Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Okt 23, 2026 · NCT07024706A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Beth Israel Deaconess Medical Center (Bidmc), Boston
- Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 23, 2026 · NCT06943872A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Brigham and Women's Hospital, Boston
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 23, 2026 · NCT07020533Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 21, 2026 · NCT06043674Understanding Chronic Lymphocytic Leukemia
- Dana Farber Cancer Institute, Boston
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 13, 2026 · NCT04028531Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
- Dana-Farber Cancer Institute, Boston
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 13, 2026 · NCT00131014Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 6, 2026 · NCT07061951A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07277231A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06973187Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Tufts Medical Center, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT03666000Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Massachusetts General Hospital, Boston
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT04588922Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT07426484Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
- Massachusetts General Hospital, Boston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT06849713Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Dana-Farber Cancer Institute, Boston
- Dana Farber Cancer Institute at St. Elizabeth's, Brighton
- Dana Farber Cancer Institute at Merrimack Valley, Methuen
- at 2 pa
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update May 7, 2026 · NCT02269592Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 13 pataas · Lahat ng kasarian · Na-update May 5, 2026 · NCT04771572A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- UMass Memorial Medical Center /ID# 270023, Worcester
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 9, 2026 · NCT06428019A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 2, 2026 · NCT06876649A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 2, 2026 · NCT06876662Study of SGR-1505 in Mature B-Cell Neoplasms
- Beth Israel Deaconess Medical Center, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT05544019Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 11, 2026 · NCT06644183Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Dana-Farber Cancer Institute /ID# 230061, Boston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 9, 2026 · NCT04895436Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
- Beth Israel Deaconess Medical Center, Boston
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ene 21, 2026 · NCT06333262Mosunetuzumab for CLL MRD Clearance
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 15, 2025 · NCT07052695AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- University of Massachusetts Memorial Medical Center, Worcester
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 10, 2025 · NCT05602363Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- South Shore Hospital, South Weymouth
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 5, 2025 · NCT05168930CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 17, 2025 · NCT04704323Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.